A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.

Clin Genitourin Cancer 2015 Apr 8;13(2):124-9. Epub 2014 Jun 8.

BC Cancer Agency, Vancouver, BC. Electronic address:

Introduction: Pazopanib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor. In this randomized, open label phase II study, pazopanib alone or in combination with bicalutamide was evaluated in patients with chemotherapy-naive castration-resistant prostate cancer (CRPC).

Patients And Methods: Patients received either pazopanib 800 mg daily (arm A) or pazopanib 800 mg plus bicalutamide 50 mg daily (arm B). A 2-stage study design was used, and the primary endpoint was prostate-specific antigen (PSA) response rate (defined as a confirmed ≥ 50% decline from baseline).

Results: A total of 23 patients (arm A, 10; arm B, 13) were accrued. The main grade 3+ toxicities were hypertension, fatigue, decreased lymphocytes, and increased alanine transaminase. Owing to significant toxicity, the protocol was amended after the first 11 patients and the pazopanib starting dose was reduced to 600 mg daily. In arm A, of 9 evaluable patients, there was 1 patient (11%) with a PSA response, 3 (33%) with stable PSA, and 5 (56%) with PSA progression; in arm B, of 12 evaluable patients, there were 2 patients (17%) with PSA responses, 6 (50%) with stable PSA, and 4 (33%) with PSA progression. Median progression-free survival was similar in both arms at 7.3 months (95% CI, 2.5 months to not reached). Long-term stable disease was seen in 4 patients who remained on treatment for 18 months (arm A), 26 months (arm A), 35 months (arm B), and 52 months (arm B).

Conclusion: In this unselected patient population, pazopanib either alone or in combination with bicalutamide failed to show sufficient activity to warrant further evaluation. However, 4 patients had long-term benefit, suggesting that targeting the VEGFR pathway may still be relevant in selected patients and emphasizing the need for improved predictive markers for patients with CRPC.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259891PMC
April 2015
29 Reads

Publication Analysis

Top Keywords

months arm
16
daily arm
12
arm months
12
patients
12
arm
10
psa progression
8
pazopanib combination
8
pazopanib 800
8
psa response
8
arm evaluable
8
evaluable patients
8
prostate cancer
8
stable psa
8
combination bicalutamide
8
castration-resistant prostate
8
phase study
8
pazopanib
7
psa
7
months
6
patient 11%
4

Similar Publications